Skip to main content

Bentsur Ron's Form 4 filing

Nuvectis Pharma, Inc. (NVCT) · filed Aug 22, 2022

Accession no.
0001104659-22-093128
Filed
Aug 22, 2022
Trade date
Aug 18-19, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions. Open-market purchases total $168.7K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bentsur RonCIK 0001251213Director, Officer (Chairman & CEO), 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 18, 2022Common StockPPurchaseAcquired+14,426$8.58F1+$123,775.083,002,409Direct
Aug 19, 2022Common StockPPurchaseAcquired+5,000$8.99+$44,9503,007,409Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Reflects the weighted average purchase price. The range of prices for the shares purchased was $8.55 to $8.60. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)